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Abstract: Confection with Hepatitis B virus (HBV) and HIV is common, with 70-90% of HIV-infected individuals 
in the United States having evidence of past or active infection with HBV.However, in Asia and sub-Saharan Africa, 
where vertical and early childhood exposure are the most common modes of transmission, respectively. Therefore, 
the prevalence of HBV among HIV-infected individuals is higher at an estimated 20-30%. One hundred and eighty- 
eight (188) HIV confirmed subjects on Highly Active Anti-retroviral Therapy (HAART), attending General Hospital 
Pankshin, Plateau state Nigeria, were enrolled for the study. Consent of the volunteers was sought after which a 
well-structured questionnaire was issued to volunteers to obtain social and demographic data. Overall result showed 
that, sixty-six 66(35%) were positive for the hepatitis B surface antigen (HBsAg).Gender distributions showed that 
18(9.6) were males compared to 48 (25.5%) females. The mean value for CD4+ cell absolute count and values of 
alanine transaminase value for HBsAg positive subjects were determined with values ranging between 211-361 
cells/µl and 25.0-27.3 I.u respectively, this is in contrast to the CD4+cell absolute count, and alanine transaminase 
values for HBsAg negative subjects whose values ranged from 181-472 cells/µl and 14.3-28.3 I.u respectively. 
Similarly, the CD4+ count of HIV/HBV co-infected subjects, who were noted to respond to HAART recorded a 
better outcome. It is therefore needful that all HIV positive patients be screened for HBsAg, while patients who lack 
the HBsAb and do not have the HBsAg positivity or occult HBV should be vaccinated against HBV so as to 
influence the clinical management of subjects on HARRT. 
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1. Introduction:  
Human immunodeficiency Virus (HIV) and 
Hepatitis B virus (HBV) are common chronic viral 
infections all over the world. They share similar 
transmission routes including sexual, blood-blood 
contact, and injecting drug usage (Saravanan et al., 
2007; Koziel and Peters,2007). Co-infection with HIV 
and HBV is very common in certain populations, such 
as intravenous drug users (IDUs) who often share the 
contaminated needles/syringes for intravenous drug 
injection. It has been reported that the world 
prevalence of HIV-HCV co-infection among IDUs 
can surpass 90% in certain populations (Maier and Wu 
2002; Aceijas and Rhodes,2000 ).It has been observed 
that HBV/HIV co-infection leads to increased 
morbidity and mortality as compared to HIV or HBV 
mono-infections, (Thio,2009). The ever increasing 
burden of these infections has become a growing 
concern [Nikolopoulos, et al., 2009]. With increased 
access to antiretroviral drugs for HIV patients, 
migrating populations and social networking by 
intravenous drug use, cases of HBV and HCV co 
infections have been on the rise (Lacombe,et al 2010), 
coupled with the dramatic rise in survival rates of 
these individuals (Sulkowski,2000). As a result of 
these factors, cases of hepatic diseases have also been 
on the rise (Sulkowski, 2002). In high-endemicity 
areas of Africa and Asia, most HBV infections occur 
in the first 5 years of life. Perinatal transmission 
predominates in East and Southeast Asia; in Africa, 
most HBV transmission occurs before the age of 5 
years, through close contact within households, 
medical procedures, traditional scarification, and, 
possibly, additional unidentified mechanisms 
(Merican,et al .,2000; Vardas,et al 1999). 
The vertical transmission rate may be lower in 
Africa than in Asia partly because of a lower 
prevalence of hepatitis B e antigen (HBeAg) in Africa, 
a major determinant of perinatal transmission 
(Roingeard et al., 1993). For these reasons, the 
prevalence of HBsAg reactivity in persons living with 
HIV infection from high HBV–endemicity areas 
reflects population prevalence. However, the 
prevalence of HBsAg reactivity could be slightly 
higher in persons who are HIV positive than in the 
general population,10% of HBV infections are 
acquired by adults, even in high-endemicity areas, 
because of transmission by sexual exposure and blood 
products; reactivation of HBV infection can occur in 
subjects with advanced HIV infection who have 
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already cleared HBsAg.Finally,worldwide prevalence 
of HBV co-infection could be estimated to be 5%–
10% in persons living with HIV infection. In countries 
where HAART is now available, liver failure has 
emerged as a major cause of death in HIV-infected 
individuals. Data from the Data Collection on Adverse 
Events of Anti-HIV Drugs (D: A: D) study suggest 
that hepatitis B accounts for 2% of deaths among 
HIV-infected persons with access to HAART Weber, 
2006]. This relatively high liver-related mortality is 
due to the accelerated course of hepatitis B in HIV-
seropositive patients. Persistent HBeAg reactivity and 
persistent high levels of HBV DNA have been 
associated with an increased progression of hepatitis B 
in HIV co-infected persons [Puoti, 2006]. 
 
2.Materials And Method 
Study Area 
The study was conducted among out patients 
attending the Pankshin General hospital in Pankshin 
LGA of Plateau state. 
Study population 
One hundred and eighty- eight (188) HIV 
confirmed subjects on Highly Active Anti-retroviral 
Therapy (HAART), attending General Hospital 
Pankshin, Plateau state Nigeria, were enrolled for the 
study. This involves HIV-Positive patients on 
HAART attending the hospital. 
Questionnaire 
A well-structured questionnaire was issued to 
obtain the demographic and other relevant data. 
Ethical Clearance 
Ethical clearance was sought and obtained from 
Pankshin General Hospital, Plateau state 
Sample Collection and analysis 
3mls of venous blood was collected, duly 
Labelled and allowed to clot and sera carefully 
separated into cryovial tubes and stored prior to the 
test at 2-8 o c, and stored at -20 O C prior use. 
HBsAg Testing 
Method 
3 r d Generation ELISA kit (clinotech diagnostics 
3 r d generation), was used for the assay of samples 
collected. 
Principle 
The clinotec diagnostic HBsAg micro titre wells 
were pre coated with monoclonal antibodies specific 
for HBsAg, the sera of particular subjects was added 
to the micro well with horseradish peroxidase (HRP) 
HBsAg if present will form antibody- HBsAg-
antibody-enzyme complex, specific immuno complex 
formed is captured on the solid phase. After washing 
to remove sample serum proteins and unbound HRP-
conjugate, chromogen solutions containing 
TetraMethylbenzidine (TMB) and urea peroxide are 
added to the wells. In the presence of Ag-Ab complex 
sandwich immunocomplex, the colourless chromogen 
is hydrolysed by the bound HRP conjugate to a blue 
coloured product. The blue colour turns yellow after 
the stop solution (sulphuric acid) is added to it. The 
amount of colour can be measured and it is 
proportional to the amount of antigen in the sample. 




One hundred and eighty-eight HIV – positive 
subjects already on HAART for the period of three 
months to five years were in this study. Out of the one 
hundred and eighty eight (188) samples screened. 
137(73%) were females and males 51(27%) as shown 
in (Table. I). 
Out of the total number of 188 patient screened 
for hepatitis B surface antigen, 66 (sixty-six) were 
screened positive (35%) and 122 samples were 
negative (65%) as shown (Table .II). 
The positivity prevalence of Hepatitis B surface 
antigen (HBsAg) were distributed among age group, 
as seen on table (.III) with each age group percentage. 
The mean CD4 absolute count for the hepatitis B 
surface antigen positive samples shows that the males 
were 361 cells/µl while 211 was recorded for the 
females subjects screened (Table. IV).The mean CD4 
absolute count and Enzyme Alanine transaminase 
mean value within age group is as shown in (table. 
V&VI). 
 
Table 1: Total Distribution Of Samples Screened 
Sex  No. Of Sample Screened  Percentage % 
Males  51  27 
Females  137  73 
Total  188  100 
 
Table 2: Distribution of Positive Samples Screened For HBsAg Based On Sex 
Sex  No.Of Positve.  %  No Of Negative  % 
Males  18  27  33  27 
Females  48  73  89  73 
Total  66  100  122  100 
 





Table 3: Distribution Of Positive Samples Screened Based on Age of subjects screened 
Age  Male  %  Female  % 
0-10  1 0.53  0  0 
11-20  0  0  2  1.06 
21-30  5  2.65  25  13.29 
31-40  7  3.72  15  7.95 
41-50  5  2.65  6  3.19 




Table 4: CD4+ Absolute Count Value And Alt Value For Hbsag Positive Subjects 
Sex  No.  Cd4+(Abs) Count  Alt Value. 
Males  18  361  25.0 
Females  48  211  27.3 
 
 
Table 5: Mean CD4 +Absolute Count For Hbsag Negative Subjects 
Age  No Of Samples  CD4+(ABS)Value 
0-10  6   388 
11-20  13  472 
21-30  33  385 
31-40  47  331 
41-50  16  387 
51-60  4  471 




Hepatitis B virus in HIV infected individuals 
varies with the population studied (Alter; 2005). 
Hepatitis B virus is a well-documented opportunistic 
pathogen among HIV infected individuals, Thio; 
(2002). From the result obtained in this study a total of 
one hundred and eighty-eight subjects screened sixty-
six (66), were sero-positive to the HBsAg;This is in 
agreement to the study conducted by Dhannvijay et al 
1999, in a study in central states of India where 28% 
of HIV infected individuals harbored the Hepatitis B 
virus. However a low prevalence was recorded in a 
study by Ramanamma and Ramani (2000) 14.3% 
Hepatitis B positive cases. In another study conducted 
by Zago, et al, (2007) in a Brazilian STD clinic 37.6% 
of the HIV Positive attendees screened were positive 
for HBsAg, which is similar to the result recorded in 
this study. Further works in the Europe confirmed 
that, Hepatitis B virus infection has been found in 6-
14% of HIV positive patients, (UNAIDS, 2005), the 
multidimensional immune suppression by HIV could 
compromise one’s ability to recover spontaneously 
from acute hepatitis B virus infection, thus leading to 
a chronic disease. The prevalence of hepatitis B 
surface antigen (HBsAg) among HIV individuals 
particularly in sub Saharan African has been given 
less attention, thus, there is a need for further studies 
and documentation and records in the sub Saharan 
Africa. 
Considering gender; a higher 25.5% positivity 
was recorded amongst the female’s subjects. This is 
contrary to the agreement with studies of Avikar, et al 
2000, De los Angeles et al 2004 and Konopniki et al 
2005); which recoded a higher rate of male HIV 
positive patients associated with HBV compared to 
females. However, on regional bases Lesi et al (2008); 
in Lagos reported prevalence’s of 9.2% for Hepatitis 
B virus  in Nigeria, while in Northern India, the ranges 
were 2.5%-5.3% for HBV co infection in HIV positive 
individuals as reported by Gupta, (2006). A study 
conducted by Tripathi et al (2007) reported prevalence 
of 77.3% among prisoners in Italy. In the study, 
results show 35% prevalence of the Hepatitis B 
surface antigen among the population studied. 
The low CD4+ count obtained in subjects who 
are HBsAg, positive may suggest a more severe 
clinical course of HIV than those who are HBsAg. 
Negative. The HIV may destroy the CD4+- 
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lymphocytes, which are normally activated to combat 
HBV infection and stop disease initiation and 
progression. Table.V, shows that the mean value of 
CD4+ absolute count between the age groups record a 
mean age of 37years which showed increased inCD4+ 
absolute count .The best prognostic indicator of 
progression to aids in HIV infection is the number of 
CD4+ cells in the peripheral blood, if this number is 
less than 200/µl, there will be probable continued 
decline in CD4+ number, in such a patients leading to 
full blown AIDS. From the result of the CD4+ count 
and ALT(Alanine transaminase) assayed, for HBsAg 
positive samples it was observed that , despite an 
increase in the value of CD4+ count the enzyme level 
was found to be on steady increase, contrary it was 
observed that individuals that are negative for the 
HBsAg showed an appreciable rise in ALT. This 
could be attributed to the effects of the HAART on 
those patients. A sudden increase in blood levels of 
alanine transaminase , an enzyme that indicates liver 
inflammation amongst HIV/HBV co infected 
individuals, such a sudden increase may be as a result 
of the commencement of HAART. 
 
Conclusion  
There is an increasing evidence of Hepatitis B 
surface antigen (HBsAg) positivity among HIV – 
positive patients from this study. This is probably due 
to the shared transmission pathways; hence the 
phenomenon of HIV and hepatitis B virus co infection 
is a cause for concern. Treatment of either hepatitis B 
virus or HIV is complex because of pharmacokinetics 
interactions’ with components of HAART regimens. 
The medical community in Nigeria needs to be alert 
on this issue, while vaccination be encourage for those 
not yet infected. Also there should be periodic review 
of co infected patients more often .The CD4+ and 
enzyme alanine transaminase of co-infected patients 
should be a priority in care and monitoring of all co-
infected patients most importantly, the general public 
should be educated on the e danger involved in a dual 
infection of HBV/HIV. 
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